已收盘 12-19 16:00:00 美东时间
-0.015
-1.20%
Rafael Holdings, Inc. completed a $25 million rights offering, resulting in $4 million from shareholders and $21 million from CEO Howard Jonas and affiliates for regulatory efforts and potential launch of Trappsol® Cyclo™ in Niemann-Pick Disease Type C1.
06-04 20:01
Shares of Exicure, Inc. (NASDAQ:XCUR) rose sharply in today's pre-market tradin...
2024-09-16 18:07
01:58 PM EDT, 08/22/2024 (MT Newswires) -- Health care stocks were lower Thursday afternoon, with the NYSE Health Care Index marginally lower and the Health Care Select Sector SPDR Fund (XLV) shedding 0.4%. The iShares Biotechnology ETF (IBB) fell past 1%. In corporate news, Evolent Health (EVH) sha...
2024-08-23 01:58
09:28 AM EDT, 08/22/2024 (MT Newswires) -- US stocks look set to open marginally higher in Thursday's trading session as initial jobless claims met analyst forecasts, and investors await additional economic data coming out later in the day. The Dow Jones Industrial Average futures were up 0.1%, S&P ...
2024-08-22 21:28
08:27 AM EDT, 08/22/2024 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% higher in Thursday's premarket activity, ahead of the US central bank's annual economic summit in Jackson Hole, Wyoming, ...
2024-08-22 20:27
08:14 AM EDT, 08/22/2024 (MT Newswires) -- US stock futures were moving slightly higher in Thursday's premarket session as investors awaited data on initial jobless claims, manufacturing and services PMIs, and existing home sales, which will be released later in the morning. The Dow Jones Industrial...
2024-08-22 20:14
07:20 AM EDT, 08/22/2024 (MT Newswires) -- Rafael Holdings (RFL) has agreed to merge with Cyclo Therapeutics (CYTH), the companies said Thursday. Under the terms of the deal, Rafael Holdings will issue class B common shares to Cyclo shareholders, on an exchange ratio valuing Cyclo shares at $0.95 pe...
2024-08-22 19:20
On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings at its cash value combined with the value of its marketable securities and certain other investments...
2024-08-22 18:52